Fermion Oy Fermion Oy

X
[{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Pacira BioSciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' Phase IV Study Showed Superior Tolerability and Efficacy of Aimovig\u00ae Compared to Topiramate in Migraine Prevention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport\u00ae in Five Therapeutic Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Ipsen"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD\u00ae-treated RMS Patients Mount Protective Antibody Response to Common Vaccines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Merck & Co"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis To Present Broad Range of Portfolio Data At ECTRIMS, Reinforcing Long-Standing Commitment to People Living with Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kesimpta\u00ae (ofatumumab) Data at ECTRIMS Highlights Preservation of Ig G Levels and Safety Experience Over Extended Exposure (~3.5 Years) in People Living with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emgality\u00ae Versus Nurtec\u00ae ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on the Phase 4 Confirmatory Study of ADUHELM\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Biogen"},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New MAVENCLAD\u00ae Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Merck Group"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO\u00ae in Pediatric Patients Following Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Baudax Bio"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Submits Final Protocol for ADUHELM\u00ae (aducanumab-avwa) Phase 4 ENVISION Trial to FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Biogen"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva\u2019s 3rd Interim Analysis of PEARL Real-world Study on AJOVY (fremanezumab) Reveals Sustained Long-term Effectiveness in Reducing Frequency, Duration and Severity of Attacks in Patients with Chronic and Episodic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Phase IV UNITE Study Shows AJOVY\u00ae (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB\u00ae with Potential Advantages Compared to Cal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Scilex Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Elyxyb (celecoxib) is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties. Celecoxib inhibits prostaglandin synthesis, primarily via inhibition of COX-2. It is being developed for migrane pain.

            Lead Product(s): Celecoxib

            Therapeutic Area: Neurology Product Name: Elyxyb

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ajovy (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. it's used for patients with chronic and episodic migraine.

            Lead Product(s): Fremanezumab-vfrm

            Therapeutic Area: Neurology Product Name: Ajovy

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AJOVY (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. it's used for patients with chronic and episodic migraine.

            Lead Product(s): Fremanezumab-vfrm

            Therapeutic Area: Neurology Product Name: Ajovy

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Andexxa (andexanet alfa) is a recombinant modified human factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

            Lead Product(s): Andexanet Alfa

            Therapeutic Area: Neurology Product Name: Andexxa

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AUSTEDO (deutetrabenazine) Tablets is first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by U.S. Food and Drug Administration in adults for treatment of tardive dyskinesia and for treatment of chorea associated with Huntington’s disease.

            Lead Product(s): Deutetrabenazine

            Therapeutic Area: Neurology Product Name: Austedo

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The confirmatory ENVISION trial is a requirement based on FDA’s accelerated approval of ADUHELM® (aducanumab-avwa), a monoclonal antibody directed against amyloid beta, 100 mg/mL injection for intravenous use in early Alzheimer’s disease.

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: Aduhelm

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Anjeso (meloxicam) injection, a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities, which are believed to be related to the inhibition of COX-2 and subsequent reduction in prostaglandin biosynthesis.

            Lead Product(s): Meloxicam

            Therapeutic Area: Neurology Product Name: Anjeso

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            New real-world data show MAVENCLAD® (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide in relapsing multiple sclerosis patients.

            Lead Product(s): Cladribine

            Therapeutic Area: Neurology Product Name: Mavenclad

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: Aduhelm

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The accelerated approval of ADUHELM in the United States has been granted based on data from clinical trials showing the effect of ADUHELM on reducing amyloid beta plaques, a surrogate biomarker that is reasonably likely to predict clinical benefit.

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: Aduhelm

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY